BACKGROUND & AIMS: In the past decade, there has been a growing epidemic of
Clostridium difficile infection (CDI). During this time, use of proton pump inhibitors (PPIs) has …

AIM To perform a systematic review and meta-analysis on proton pump inhibitors (PPIs)
therapy and the risk of Clostridium difficile infection (CDI). METHODS We conducted a …

Introduction Emerging epidemiological evidence suggests that proton pump inhibitor (PPI)
acid-suppression therapy is associated with an increased risk of Clostridium difficile …

BACKGROUNDClostridium difficile is the principal infectious cause of antibiotic-associated
diarrhea and accounts for 12% of hospital-acquired infections. Recent literature has shown …

Attention has recently been directed toward a plausible link between Clostridium difficile
infection (CDI) and proton-pump inhibitors (PPIs). However, the results of studies on the …

Background Clostridium difficile infection (CDI) is a cause of increased morbidity and health
care costs among hospitalized patients. Proton pump inhibitors (PPIs) are mainly used for …

Background: Proton pump inhibitors (PPIs) are among the most commonly used medications
by patients due to its availability over the counter and frequent prescribing by physicians to …

Background Considering the incidence and severity of Clostridium difficile infection (CDI),
risk reduction strategies are crucial. Prior studies suggest that proton pump inhibitor (PPI) …

OBJECTIVES: Several studies have raised concern regarding the possible association
between proton-pump inhibitors (PPIs) andClostridium difficileinfection (CDI). We aimed to …

OBJECTIVES: Clostridium difficile-associated diarrhea (CDAD) is a major cause of morbidity
and increasing health-care costs among hospitalized patients. Although exposure to …